A B ‐Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted therapies
ConclusionThe BRAF signature may better help guide targeted therapy for melanoma, and such a framework can be applied to other cancers and mutations to provide more information than mutation status alone.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Kevin Yao,
Emily Zhou,
Chao Cheng Tags: RESEARCH ARTICLE Source Type: research
More News: Cancer | Cancer & Oncology | Genetics | Immunotherapy | Melanoma | Skin | Skin Cancer | Study